SSS Weekend 2018
March 23-25th
Arabella Hotel Waldhuus Davos

23rd annual research meeting of the USZ Department of Dermatology

Chair: Prof. Lars E. French
Dear colleagues

Welcome to the 2018 issue of Science, Snow, and Sun (SSS) Meeting in Davos, the annual research retreat of the USZ Department of Dermatology. After many years in Hotels Clavadel and Schatzalp and one year only in Hotel Amaron (for reasons that may be un-blinded during this year’s meeting), we have moved closer to the cross-country slopes (Langlaufzentrum) and will stay in four-star Arabella Hotel Waldhuus. It is a traditional Hotel but with modern and convenient conference rooms that will make our seminar comfortable and enjoyable.

The scientific programme of 2018 is the biggest in the history of twenty-three SSS meetings. We will have 40 short presentations from master students, PhD students, postdocs, scientists, and clinicians, and the meeting should therefore resemble the broad research activity in our department. We will have five sessions split on Friday (3) and Saturday (2), and the presentations will typically be 10 minutes, hence, comparable with the time we are given as presenters at international meetings. However, also this year, we will have some longer keynote lectures presented by experienced researchers in most research groups. The keynote laureates this year are Annalisa Saltari, Eleni Varypataki, Serena Grossi, Antonia Fettelschoss, Rebecca Higgins, Mark Mellett, and Omar Hasan Ali.

The meeting is framed with social ventures and culinary journeys such as Friday night dinner, Saturday night Fondue, and of course, the compulsory outdoor activities on Saturday afternoon and Sunday, so bring your best dress and best ski outfit!

We appreciate the financial support from our Silver sponsor Janssen-Cilag and Gold sponsor Takeda Pharmaceuticals.

Welcome to Davos!

Lars E. French, Thomas M. Kündig, Philipp Bosshard, Pål Johansen
Scientific programme

Friday 23rd March

Session 1. Chair: Steve Pascolo
10.45  Philipp d’Boss Welcome and general introduction
10.55  Barbara Meier Impact of innate immunity in acute generalized exanthematous pustulosis
11.05  Annalisa-Saltari Modulation of CD271 in melanoma as a new therapeutic strategy to overcome drug resistance
11.25  Melanie Maudrich FACS in melanoma research
11.35  Sabrina Schindler Biomarkers for immunotherapies in melanoma patients
11.45  Corinne Stoffel Functional characterization of PKC function in targeted therapy resistance in cutaneous metastatic melanoma
11.55  Andreas Dzung The role of STK11 in melanoma
12.05  Yun-Tsan Chang Ineffective antibody-dependent cellular cytotoxicity in patients with cutaneous T cell lymphoma
12.15  Tanja Eberle Cytokine signature of tumor T cells in Sezary Syndrome
12.25  Elina Stoffel Analysis of anti-TNF-induced skin lesions reveals strong Th1 activation with some distinct immunological characteristics
12.35  Lunch

Session 2. Chair: Dietmar Beer
15.45  Desislava Ignatova Malignant T cells inhibit anti-cancer and anti-infectious immunity in cutaneous T cell lymphoma
15.55  Eleni Varypataki PCI-based cancer vaccination: Bypassing T-cell help
16.15  Marina Tusup Immunomodulation by RNA
16.25  Steve Pascolo mRNA platform
16.35  Alessandra Cereghetti Reversing melanoma immune escape and invasiveness using novel targeted agents
16.45  Lara Grossmann Real life experience with Vismodegib in tertiary skin cancer referral centre
16.55  Florentia Dimitriou LAG3 characterization of targeted therapy and immunotherapy on metastatic melanoma and it’s potential as a biomarker
17.05  Coffee break

Session 3. Chair: Mitch Levesque
17.40  Alice Langer The Biobank: Update 2018
17.50  Anja Irmisch Comprehensive molecular analysis of melanoma patients for the molecular tumor board
18.00  Corinne Eggenschwiler Accidental hyperpigmentation and laser therapy
18.10  Egle Ramelyte Fine-needle aspiration (FNA) in skin sampling
18.20  Phil Cheng Integration of omics and clinic
18.30  Serena Grossi Caspase-dependent cleavage of a previously unidentified substrate supports cell death
18.50  Gabriele Fenini The essential role of the NLRP1 inflammasome in human primary keratinocytes
19.00  Antonia Fettelschoss Therapeutic vaccination of companion animals to treat chronic diseases and allergies
19.20  End of session
20.00  Dinner in the Hotel Restaurant
Saturday 24th March

Session 4. Chair: Philipp Bosshard

08.00  Ossia Eichhoff  Discovery of novel inhibitors for treatment-resistant melanoma by high-throughput compound screening
08.10  Ishani Banik  In vivo screening of functional novel oncogenic driver mutations in zebrafish melanoma model
08.20  Paulina Hennig  Crosstalk between inflammasome and Nrf2
08.30  Michela de Filippo  Dermal-Epidermal crosstalk in 3D skin models during inflammation and cancer: project overview
08.40  Gaia Restivo  – 3D skin models of Basal Cell Carcinoma (BCC) as a tool for drug testing
08.50  Eugen Bersuch  Prospective longitudinal observational research study to investigate the remission of atopic dermatitis and associated allergic diseases
09.00  Bettina Schmid  The role of *Malassezia* spp. in atopic dermatitis
09.10  Anna Medovarski  Routine identification of *Treponema pallidum* and herpes simplex viruses with a multiplex PCR: 4 years of experience
09.20  Linda Grillova  Molecular characterization of *Treponema pallidum* subsp. *pallidum* in Switzerland and France with a new multi-locus sequence typing scheme

09.40  Coffee break

Session 5. Chair: Thomas M. Kündig

10.10  Alexandra Vent  Bicarbonate admixture to local anaesthesia: a double-blind, randomized clinical trial
10.20  Rebecca Higgins  – Genetic architecture of linear localized scleroderma
10.40  Adhideb Ghosh  – JAK2 mutation in pyoderma gangrenosum
10.50  Julia-Tatjana Maul  Safety of systemic psoriasis treatments evaluated in the Swiss Dermatology Network for Targeted Therapies (SDNTT)
11.00  Alshimaa Mostafa  Clinical epidemiology of pustular psoriasis
11.10  Mark Mellett  CARD14 plays a pivotal role in driving psoriasis pathogenesis
11.30  Omar Hasan Ali  Pre-existing autoantibodies against Collagen XVII favor the development of cutaneous immune-mediated adverse events during checkpoint inhibitor therapy

11.50  End of meeting with closing remarks

19.30  Gathering in the reception for the common stroll to the external fondue restaurant